Clyburn Issues Statement on Authorization of Coronavirus Vaccines for Young Children

Washington, D.C. (June 17, 2022) – Today, Rep. James E. Clyburn, Chairman of the Select Subcommittee on the Coronavirus Crisis, issued the following statement on the Food and Drug Administration's (FDA) emergency use authorization of a three-dose Pfizer vaccine for children under 5 and a two-dose Moderna vaccine for children under 6. In May, Chairman Clyburn requested a staff briefing with the FDA following public reports that the review of a vaccine for young children was purposely delayed. Agency leadership noted at the briefing: "We see case counts rising, we feel urgency, we will move as fast as we can on reviews." Last week, the Biden Administration released an operational plan to ensure these vaccines are readily available to families as soon as they are recommended by the Centers for Disease Control and Prevention.

"Following today's FDA emergency use authorization of two coronavirus vaccines for young children, Americans of all ages will be able to take advantage of the protection the shots provide against severe illness and death due to COVID-19. I applaud the tireless work of the scientists who have enabled us to reach this milestone long anticipated by American parents in our nation's fight against this disease. As the Biden-Harris Administration works to distribute and administer doses to young children effectively, efficiently, and equitably, I urge Americans to ensure that all of their family members are fully vaccinated and, if and when eligible, boosted so that their protection remains strong and up to date. I also remain committed to rigorous oversight of the FDA to ensure that authorizations of future vaccines are not unnecessarily delayed."